55 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
-antibody- conjugates, or DACs. These partnerships allow us to advance and accelerate our research and enable access to additional capabilities and expand … receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determines
8-K
EX-10.2
ptii01lvhndtjw
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-10.1
byo6io v6
30 May 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
3rimoelrl164n80
4 May 23
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
7:34am
ARS
mdhhhjec3c
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
ttke8x2h pi
18 Apr 23
Preliminary proxy
7:59am